HeRO ™ graft bypass the central vein stenosis, improve blood dialysis

HeRO Graft - hemodialysis is reliable

Central venous stenosis is a common and serious long-term hemodialysis patients with vascular complications, which can lead to loss of vascular access and shortened life expectancy.To bypass the vein stenosis and improve long-term hemodialysis adequacy, has created all kinds of permanent subcutaneous arteriovenous graft device, as already used up all the other solution path choice of hemodialysis patients.

A technique called HeRO ™ graft such products approved by FDA in 2008.Compared with the catheter, it is the only proved by clinical pathways related infection risk can be reduced 69% of the permanent subcutaneous arteriovenous grafts, improve the adequacy of hemodialysis to 32% (1.7Kt/V), and will maintain intervention measures to reduce the channel function more than half.1The research will also be HeRO Graft with a higher cumulative patency rate of up to 87% two years together.2

Use HeRO grafts also have cost saving advantages.A provide hemodialysis pathway of American health care model forecast, compared with the catheter, using a HeRO graft can save the cost of 23% per year on average.3Can save more than dialysis centerThe $3000Per patient per year.4The hospital can save thousands of the high admission fees due to equipment related infections - usually between infection rateThe $23 ktoThe $56 kCheck in at a time.5 or 6

What makes HeRO graft so unique?

Unlike other transplant products, HeRO graft is not dependent on the venous anastomosis to bypass the vein stenosis.Instead, with resistance to twisting and crushing nickel titanium alloy braid reinforcement opaque ray silicone venous outflow components placed in the right atrium, titanium and through proprietary connector firmly connected to the adjacent ePTFE blood dialysis grafts.This mechanism allows the blood from the back to the heart artery.

To know more information about the HeRO graft and how to apply it to your practice, please sign up for the coming on March 30 to 31 in Houston methodist technology, innovation and education institute in Houston, Texas (MITIE) Think HeRO training courseSMAnd can talk with your Merit representative or visitMerit.com/EducationTo sign up

  1. Katzman has, H., McLafferty, R., Ross, j., Glickman, m., Peden, e., & Lawson, j. (2009). The Initial experience and outcome of a new hemodialysis access device for catheter - dependent patients. J Vasc Surg,50(3) : 600-607. E1.
  2. Gage, s., Katzman has, H., Ross, j., Hohmann, s., Sharpe, C., Butterly, D., & Lawson, j. (2012). Multi - center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] Graft implants for Hemodialysis treatment. Eur J Vasc Endovasc Surg, 44 (1) : 93-99.
  3. Dageforde, l., Bream, P., & Moore, d. (2012). Hemodialysis Reliable Outflow (HeRO) device in the end - stage dialysis access: a decision analysis model. J Surg Res, 177, (1) : 165-171.
  4. Yost, l., Dinwiddie, l. (2010, Nov.). The Impact of the use of the HeRO vascular access graft vs. tunneled dialysis catheters on dialysis provider economics in an era of bundling. Poster session presented at the ASN, American Society of Nephrology, Denver, CO.
  5. Ramanathan, V., Chiu, E., Thomas, J., a. Khan, Dolson, g., & Darouiche, r. (2007). Healthcare costs associated with hemodialysis catheter - related infections: A single ‐ center experience. Infect Control Hosp Epidemiol, 28 (5) : 606-609.
  6. O Grady, N., Dellinger, e. Gerberding, Heartd, s. J., Maki, D., Masur, h. r. McCormick, Mermel, l., Pearson, m., Raad, i., Randolph, A., & Weinstein, r. (2002). The Guidelines for the prevention of intravascular catheter - related infections. The Hospital Infection Control Practices Advisory Committee, Center for diseases Control and prevention, the U.S. Pediatrics, 110 (5) : e51.